AdaptHealth (NASDAQ:AHCO) Price Target Cut to $15.00 by Analysts at Robert W. Baird

AdaptHealth (NASDAQ:AHCO) had its price objective lowered by Robert W. Baird from $18.00 to $15.00 in a research note published on Monday, MarketBeat reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other brokerages also recently weighed in on AHCO. Canaccord Genuity Group raised their price objective on AdaptHealth from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen raised shares of AdaptHealth from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Jefferies Financial Group reiterated a “hold” rating and issued a $11.00 target price on shares of AdaptHealth in a report on Monday, April 20th. Truist Financial boosted their price objective on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of AdaptHealth in a research report on Friday, May 22nd. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.86.

AdaptHealth Stock Up 1.3%

Shares of AdaptHealth stock opened at $10.40 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.92 and a quick ratio of 0.71. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -16.64, a P/E/G ratio of 0.55 and a beta of 1.45. The stock has a 50-day simple moving average of $10.66 and a 200-day simple moving average of $10.62. AdaptHealth has a 52-week low of $8.51 and a 52-week high of $13.43.

Insider Activity

In other news, insider Russell E. Schuster III sold 11,275 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $10.06, for a total value of $113,426.50. Following the completion of the transaction, the insider owned 136,538 shares in the company, valued at approximately $1,373,572.28. This represents a 7.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.95% of the company’s stock.

Institutional Trading of AdaptHealth

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its holdings in shares of AdaptHealth by 386.3% during the fourth quarter. SG Americas Securities LLC now owns 78,141 shares of the company’s stock worth $778,000 after purchasing an additional 62,073 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in AdaptHealth by 15.2% during the 4th quarter. Kennedy Capital Management LLC now owns 2,408,038 shares of the company’s stock worth $23,984,000 after acquiring an additional 317,900 shares during the last quarter. Reinhart Partners LLC. grew its holdings in AdaptHealth by 10.6% during the 4th quarter. Reinhart Partners LLC. now owns 8,100,785 shares of the company’s stock worth $80,684,000 after acquiring an additional 773,727 shares during the last quarter. Hudson Edge Investment Partners Inc. acquired a new stake in AdaptHealth in the 4th quarter valued at about $614,000. Finally, Aristeia Capital L.L.C. bought a new position in shares of AdaptHealth in the fourth quarter worth about $749,000. Institutional investors own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.